Navigation Links
The University of Sydney and ResMed partner to accelerate research in sleep-disordered breathing and biomedical engineering
Date:5/13/2013

SYDNEY, May 13, 2013 /PRNewswire/ -- The University of Sydney and ResMed Limited today announced a new partnership that includes significant and long-term funding of research at the University, ultimately benefitting the hundreds of millions of sufferers of sleep-disordered breathing worldwide.

(Logo: http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO)

(Logo: http://photos.prnewswire.com/prnh/20130513/LA12842LOGO)

Under an agreement recently reached between the parties, ResMed Limited will pay $AU25 million to the University to support its work, including the establishment of two perpetual academic chairs called the ResMed Chair of Sleep Medicine for sleep-disordered breathing with a focus on chronic disease and the ResMed Chair of Biomedical Engineering with an emphasis on bioinformatics research, as well as funding for research in related areas. The agreement also provides for the settlement of proceedings between the parties in the Australian Federal Court regarding a dispute over an earlier licensing agreement.

"Sleep-disordered breathing is a global health problem affecting one in five adults, with broad and deep implications in other chronic conditions, such as hypertension and heart failure," said ResMed Chief Executive Officer Michael Farrell . "With this partnership, we look forward to the University's research revealing new information on how to battle this costly and life-threatening condition."

ResMed is an innovator and pioneer in developing products for the treatment of sleep-disordered breathing and respiratory conditions including COPD. The company's Sydney campus is a manufacturing and innovation centre and headquarters for its Asia-Pacific operations and it employs more than 1,200 people locally.

The University's Vice-Chancellor, Dr Michael Spence expressed his appreciation to ResMed for such a positive contribution and said this agreement "would allow the University to further develop its path-finding research in these critically important areas, as well as provide future opportunities for our researchers."

The University of Sydney's Medical and Health Sciences Research Program is world-class, as evidenced in the 2012 Excellence in Research for Australia report which rated this program "well above world standard."

About ResMed:
ResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.Contacts:Gretchen Griswold 

Sarah StockResMed

The University of SydneyDirector, Global Corporate Communications

Head of Media and CommunicationsO: +1 858-836-6789

Ph +61 2 9114 0748 / +61 419 278 715news@resmed.com 

sarah.stock@sydney.edu.au 


'/>"/>
SOURCE ResMed Limited
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Duke University Medical Center Study Finds Prodigy Blood Glucose Monitor System Ranks Highest In Quality Among Leading Brands
2. SonaCare Medical Partners with University College London to Create Center of Excellence for HIFU Surgical Ablation Technology
3. SonaCare Medical to Integrate SmartTarget Image Registration and Fusion Software from University College London into Industry Leading Prostate HIFU System
4. Rush University Medical Center Presents Positive MuGard Clinical Data at the Oncology Nursing Society 38th Annual Congress
5. Cardinal Health Foundation, The Ohio State University Launch Fourth Toolkit to Help Reduce Abuse of Prescription Drugs on College Campuses
6. One-Time, One Dose Radiation Treatment Offered For Breast Cancer Patients At MedStar Georgetown University Hospital And MedStar Washington Hospital Center
7. Walgreens Selects Webster University as Education Provider
8. New Autism Detection System Commercialized through Partnership of IP Shakti, LLC and Shizuoka University
9. Fuisz llc Announces Induction of Richard C. Fuisz, M.D., into Georgetown Universitys 1789 Society.
10. Millennium Research Group Sponsors Case Competition at Western University for Second Year
11. Denmarks Odense University Hospital Orders Elektas New Versa HD Linear Accelerator for Radiotherapy Treatment of Patients with Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... LONDON , May 24, 2016 ... erfüllt beide primären Endpunkte ... und Überlegenheit in ‚ausgezeichneter plus guter ... aufsteigenden Colons    ,      (Logo: ... B.V. gab heute neue positive Daten von der ...
(Date:5/24/2016)... -- NxStage Medical, Inc. (Nasdaq: NXTM ), a ... today announced that Jeffrey H. Burbank , Chief ... of investor conferences. Where applicable, a webcast of the ...   ... Friday, June 10, 2016 1:30 p.m. ET ...
(Date:5/24/2016)... HONG KONG , May 24, 2016 /PRNewswire/ ... primer stent de doble terapia del mundo, introduce ... fístula arteriovenosa. OrbusNeich, una compañía global ... cambian las vidas, ha expandido su cartera incluyendo ... catéteres balón JADE™ y Scoreflex™ PTA son los ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... Saint Francis Hospital ... years, and the efforts have paid off. Since implementation of these efforts, ... care to enhance perioperative patient experiences and reduce costly complications. Since implementation in ...
(Date:5/26/2016)... ... May 26, 2016 , ... Development Team of Pixel ... for FCPX. , "This new layered style transition tool will keep a consistent flow ... CEO of Pixel Film Studios. , TranSweep is an all new layered style ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... industry leader in Blood Pressure products . , High blood pressure affects ... effects. Left untreated, high blood pressure can lead to heart disease, stroke, kidney ...
(Date:5/25/2016)... ... May 26, 2016 , ... The United States Food and Drug Administration ... both men and women. To date, the company is the first and only manufacturer ... adult who suffers with androgenetic alopecia. , “This new level of clearance substantiates ...
(Date:5/25/2016)... ... 25, 2016 , ... The Georgia State University College of Law new building ... Design Commission. , The annual award recognizes projects, programs, individuals and organizations that have ... of its physical heritage and the balance between the old and the new. , ...
Breaking Medicine News(10 mins):